Compare AIN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | DNTH |
|---|---|---|
| Founded | 1895 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 1994 | 2018 |
| Metric | AIN | DNTH |
|---|---|---|
| Price | $54.04 | $78.51 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $60.25 | ★ $121.90 |
| AVG Volume (30 Days) | 291.7K | ★ 1.1M |
| Earning Date | 06-01-2026 | 06-01-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,054,132,000.00 | $2,036,000.00 |
| Revenue This Year | $2.89 | N/A |
| Revenue Next Year | N/A | $58.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.29 | N/A |
| 52 Week Low | $41.15 | $13.37 |
| 52 Week High | $75.16 | $88.45 |
| Indicator | AIN | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 70.18 |
| Support Level | $52.23 | $34.83 |
| Resistance Level | $60.43 | N/A |
| Average True Range (ATR) | 2.02 | 4.87 |
| MACD | -0.61 | 2.04 |
| Stochastic Oscillator | 18.88 | 72.63 |
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.